Viz.ai

What is Viz.ai and who sells it?

Viz.ai calls its product an "AI-powered care coordination platform" linking patients, clinicians and treatments, built on more than 50 imaging-analysis algorithms (Viz.ai website, October 2026). The suites it lists are Viz Neuro, Vascular, Cardio, Pulmonary, Radiology, Trauma and Oncology. Neuro covers aneurysm, CT perfusion, hemorrhage, large-vessel occlusion, subdural and post-acute stroke. Vascular covers aortic disease and pulmonary embolism. Cardio covers hypertrophic cardiomyopathy, acute coronary syndrome and cardiac amyloidosis. The company also sells Viz Assist, Viz Agent Studio, which lets health systems build their own AI care pathways, and a Viz Life Sciences offering.

Viz.ai, Inc. was founded in 2016 by Chris Mansi and Manoj Ramachandran and is headquartered in San Francisco, with research and development in Israel (Tracxn). A $100M Series D in April 2022 was led by Tiger Global and Insight Partners at a $1.2B valuation, bringing total funding to about $250M, according to Calcalist and the company's announcement. Tracxn lists a further $40M debt financing in March 2023. Kleiner Perkins is a named backer.

A July 28, 2026 company release says the platform is embedded in 2,000 hospitals, reaches 230 million patients and runs more than 50 AI care pathways. Those are vendor figures.

What does Viz.ai do well?

Viz.ai pushes a detected finding, such as a large-vessel occlusion on a CT angiogram, to a mobile app and group messaging thread and helps coordinate transfer (Viz.ai website). A 2026 paper in the Journal of Stroke and Cerebrovascular Diseases (PMID 41653946) describes integrating a Life Flight service into the Viz.ai thread.

The company's ContaCT software received the first De Novo for radiological computer-assisted triage and notification software, DEN170073, granted February 13, 2018, for large-vessel occlusion on CT angiography (FDA De Novo database).

The Trust Center lists SOC 2 Type II, a HIPAA program, ISO 27001, ISO 27701, ISO 27799, ISO 27017, ISO 27018 and ISO 27035, with reports available on request (Viz.ai Trust Center). HITRUST is not listed. The Trust Center says the platform processes PHI at 2,000 hospitals and health systems in the U.S. and Europe. The EHR and PACS integration list is not on the home page, though the site lists a Microsoft Cloud for Healthcare partnership.

How many FDA clearances does Viz.ai hold?

The vendor says 13 clearances and its home page says "over 50 advanced, FDA-cleared algorithms". The FDA database shows 12 records for the applicant "Viz. Ai, Inc.", 10 510(k)s and 2 De Novos, as queried in October 2026.

The first is DEN170073, the ContaCT De Novo. The 510(k)s run from Viz CTP in April 2018 (K180161) through Viz ICH in 2020 and 2021, Viz ANEURYSM, Viz SDH, Viz RV/LV, Viz LVO ContaCT and Viz AAA in 2022 and 2023, Viz HDS, Viz Volume Plus and Viz ICH+ in February 2024 (K232363), and Viz Subdural+ in June 2025 (K250354). The second De Novo is DEN230003, Viz HCM, a cardiovascular machine-learning notification device granted in August 2023. Indications are listed per K-number on the FDA site.

What does the evidence say?

The key study is a 2025 systematic review and meta-analysis in Translational Stroke Research (PMID 40335883), covering 12 studies and 15,595 patients. Viz.ai use was associated with shorter door-to-groin time (standardized mean difference of -0.47) and shorter door-in-door-out time (-0.49). The review found no significant difference in clinical outcomes.

The Viz.ai news pages include studies funded by the vendor. The Life Flight paper above is an implementation report and not an outcome trial.

How does Viz.ai compare with Aidoc and RapidAI?

Web comparisons pair Viz.ai most often with Aidoc, and RapidAI is the third frequent name. The wider radiology set is Annalise.ai, Qure.ai and MaxQ, and a 2026 Medicina scoping review also names Brainomix. Viz.ai starts from the care team's phone and from stroke, then widens to cardiology and other pathways. Aidoc starts from the radiology worklist.

How much does Viz.ai cost?

Viz.ai lists no price. Access is through a demo request and an enterprise sales process.

Who is Viz.ai for?

A neurointerventional program at a thrombectomy-capable stroke center, working with spoke hospitals that transfer patients, is the clearest fit, because the meta-analysis time savings are in door-in-door-out and door-to-groin intervals. A cardiology service interested in finding patients with hypertrophic cardiomyopathy or cardiac amyloidosis in existing imaging has a second use, though the pooled evidence concerns stroke. A hospital CIO looking for a platform to host its own AI models may look at Viz Agent Studio, which the vendor describes in its 2026 release.

A rural hospital with no transfer partner will pay for alerts it has nowhere to send.

The verdict

Buy Viz.ai if you run or feed a thrombectomy center and the bottleneck is the hour between scan and call. If your aim is better recoveries on their own, the pooled studies do not promise that, and a hospital without a transfer pathway has no use for the alert.